Yusuf Ilhan, M. Korkmaz, E. Güzel, K. Mammadova, S. S. Göksu, A. Tatlı, H. Coşkun
{"title":"Anti-Yo Associated Paraneoplastic Cerebellar Degeneration in Ovarian Cancer: A Rare Case Report","authors":"Yusuf Ilhan, M. Korkmaz, E. Güzel, K. Mammadova, S. S. Göksu, A. Tatlı, H. Coşkun","doi":"10.37047/JOS.2020-78768","DOIUrl":null,"url":null,"abstract":"rare neurological complication in cancer, characterized by the rapid development of cerebellar ataxia resulting from tumor-induced autoimmunity against cerebellar Purkinje cells. It is mostly seen in gynecological cancers, breast cancer, and small cell lung cancer.1 AntiYo antibody, also known as anti-Purkinje cell cytoplasmic antibody type-1 is highly specific and the most frequently found antibody in patients with PCD. Other antibodies associated with PCD are anti-Hu, antiTr, anti-Ri, and anti-mGluR1. However, no antibodies are identified in nearly 40% of PCD patients.2-4 PCD occurs in about 0.2% of patients with malignant tumors and is characterized by cerebellar symptoms such as ataxia, vertigo, and dysarthria.5 Here, we present a case of anti-Yo-associated PCD in an ovarian cancer patient.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"31-33"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37047/JOS.2020-78768","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
rare neurological complication in cancer, characterized by the rapid development of cerebellar ataxia resulting from tumor-induced autoimmunity against cerebellar Purkinje cells. It is mostly seen in gynecological cancers, breast cancer, and small cell lung cancer.1 AntiYo antibody, also known as anti-Purkinje cell cytoplasmic antibody type-1 is highly specific and the most frequently found antibody in patients with PCD. Other antibodies associated with PCD are anti-Hu, antiTr, anti-Ri, and anti-mGluR1. However, no antibodies are identified in nearly 40% of PCD patients.2-4 PCD occurs in about 0.2% of patients with malignant tumors and is characterized by cerebellar symptoms such as ataxia, vertigo, and dysarthria.5 Here, we present a case of anti-Yo-associated PCD in an ovarian cancer patient.